Akari Therapeutics Plc (AKTX)
14.55
-0.90
(-5.79%)
USD |
NASDAQ |
Jun 09, 14:43
Akari Therapeutics SG&A Expense (Quarterly) : 2.165M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Amarin Corp. Plc | 19.35M |
| DBV Technologies SA | 15.36M |
| Cellectis SA | 5.610M |
| Autolus Therapeutics Plc | 39.89M |
| Evaxion AS | 1.527M |